» Articles » PMID: 23796316

Mediators of the Effects on Fatigue of Pragmatic Rehabilitation for Chronic Fatigue Syndrome

Overview
Specialty Psychology
Date 2013 Jun 26
PMID 23796316
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine potential mediators of the effect of pragmatic rehabilitation on improvements in fatigue following a randomized controlled trial for patients with chronic fatigue syndrome (CFS/ME) in primary care (IRCTN 74156610).

Method: Patients fulfilled the Oxford criteria for CFS. Ninety-five patients were randomized to pragmatic rehabilitation and 100 to general practitioner (GP) treatment as usual. The outcome was the Chalder fatigue scale score (0123 scoring) at end of treatment (20 weeks) and 1-year follow up (70 weeks). First, the effect of treatment on potential mediators was assessed. Then fatigue was regressed on significant mediators, treatment allocation, and baseline measures of fatigue and significant mediators.

Results: Reduction in limiting activities at 20 weeks mediated the positive effect of pragmatic rehabilitation on fatigue at 70 weeks (mediated effect size = -2.64, SE = 0.81, p = .001, proportion of effect mediated = 82.0%). Reduction in catastrophizing at 20 weeks mediated the positive effect of pragmatic rehabilitation on fatigue at 70 weeks (mediated effect size = -1.39, SE = 0.61, p = .023, proportion of effect mediated = 43.2%). Reductions in 70-week measures of fear avoidance, embarrassment avoidance, limiting activities, and all-or-nothing behavior all mediated improvement in fatigue at 70 weeks, although the causal direction of these cross-sectional effects cannot be determined. There were no between-group differences on measures of exercise capacity (a timed step test).

Conclusions: Improvements in fatigue following pragmatic rehabilitation are related to changes in behavioral responses to and beliefs about fatigue.

Citing Articles

CBT and graded exercise therapy studies have proven that ME/CFS and long COVID are physical diseases, yet no one is aware of that.

Vink M, Vink-Niese A Front Hum Neurosci. 2025; 19:1495050.

PMID: 39944089 PMC: 11814198. DOI: 10.3389/fnhum.2025.1495050.


IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS).

Pressler H, Machule M, Ufer F, Bunger I, Li L, Buchholz E Trials. 2024; 25(1):172.

PMID: 38454468 PMC: 10919018. DOI: 10.1186/s13063-024-07982-5.


The Draft Report by the Institute for Quality and Efficiency in Healthcare Does Not Provide Any Evidence That Graded Exercise Therapy and Cognitive Behavioral Therapy Are Safe and Effective Treatments for Myalgic Encephalomyelitis/Chronic Fatigue....

Vink M, Vink-Niese A Diseases. 2023; 11(1).

PMID: 36648876 PMC: 9844345. DOI: 10.3390/diseases11010011.


Fatigue severity and avoidance among individuals with chronic disease: A meta-analysis.

Adamowicz J, Velez-Bermudez M, Thomas E J Psychosom Res. 2022; 159:110951.

PMID: 35665612 PMC: 9629285. DOI: 10.1016/j.jpsychores.2022.110951.


Evidence-Based Care for People with Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

Sharpe M, Chalder T, White P J Gen Intern Med. 2021; 37(2):449-452.

PMID: 34791590 PMC: 8811058. DOI: 10.1007/s11606-021-07188-4.